Products Ublituximab
Ublituximab Approved Recruiting 🔥 Hot Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Nov 28, 2025 → Aug 1, 2029
About Ublituximab Ublituximab is a approved stage product being developed by TG Therapeutics for Multiple Sclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07225361. Target conditions include Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting.
Clinical Trials (5) NCT ID Phase Status Start Completion Indication NCT06864936 Pre-clinical Recruiting Jan 1, 2026 Jun 30, 2027 Multiple Sclerosis (MS) - Relapsing-remitting NCT07225361 Approved Recruiting Nov 28, 2025 Aug 1, 2029 Multiple Sclerosis NCT04130997 Phase 3 Active Nov 18, 2019 May 31, 2032 Relapsing Multiple Sclerosis (RMS) NCT03381170 Phase 2 Completed Jun 1, 2017 Nov 11, 2022 Relapsing Remitting Multiple Sclerosis NCT01647971 Phase 1/2 Completed Jul 19, 2012 May 1, 2015 Non-Hodgkins Lymphoma
Product Company Stage Hype Score Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 NEX-20A Nanexa AB Phase 1 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2 KW-2478 + Bortezomib Kyowa Kirin Phase 1/2 ONO-2808 + Placebo Ono Pharmaceutical Phase 2 KW-2478 Kyowa Kirin Phase 1
Other Products from TG Therapeutics